Company Database
Top Healthcare Companies
The most valuable private healthcare and life sciences companies, ranked by their latest post-money valuation.
25 companies · Updated July 13, 2026
| Company | Sector | Stage | Valuation | Latest Funding | Total Funding | Headcount | Momentum | Location | Website | Business Model | Customer Profile |
|---|---|---|---|---|---|---|---|---|---|---|---|
 Juul Labs | Consumer & Commerce | Debt | $38B | (Dec 2018) | $14.12B | 1,181 | San Francisco, California | www.juullabs.com | B2B2C | Hardware Sales, Hardware + Subscription | |
 Athenahealth | Healthcare & Life Sciences | Debt | $17B | $4B (Feb 2022) | $99.7M | 1 | Boston, Massachusetts | www.athenahealth.com/ | B2B | Payment Processing Fee, Subscription SaaS, Services & Consulting | |
 Zelis | FinTech | Private Equity | $17B | (Nov 2024) | $11.4M | 3,001 | Boston, Massachusetts | www.zelis.com | B2B | Payment Processing Fee, Subscription SaaS, Revenue Share | |
 Devoted Health | Healthcare & Life Sciences | Series F Extension | $16.1B | $317M (Jan 2026) | $2.88B | 2,197 | Waltham, Massachusetts | www.devoted.com/ | B2C | Government Contracts, Services & Consulting, Subscription SaaS | |
 Biosplice Therapeutics | Healthcare & Life Sciences | VC Round | $12.44B | $120M (Aug 2018) | $658M | 30 | San Diego, California | www.biosplice.com/default.aspx | B2B | Services & Consulting | |
 OpenEvidence | Healthcare & Life Sciences | Series D | $12B | $250M (Jan 2026) | $735M | 123 | Cambridge, Massachusetts | www.openevidence.com | B2B2C | Freemium, Subscription SaaS | |
 Physicl | Healthcare & Life Sciences | Series C | $11B | $1B (Mar 2026) | $2.07B | 13 | Bordeaux | www.physicl.ai/ | B2B | Subscription SaaS, Services & Consulting | |
 Oura | Consumer & Commerce | Series E | $11B | $900M (Oct 2025) | $1.24B | 1,428 | San Francisco, California | www.ouraring.com | B2C | Hardware + Subscription, Hardware Sales, Subscription SaaS, Government Contracts, Data as a Service | |
 GVE | FinTech | Private Equity | $10.65B | $5.53M (Dec 2024) | $31.81M | - | Tokyo | www.gve.co.jp | B2G | Government Contracts, Payment Processing Fee, Services & Consulting | |
 Lila Sciences | Healthcare & Life Sciences | Series B | $10.5B | $2B (Jun 2026) | $2.79B | 445 | Cambridge, Massachusetts | www.lila.ai/ | B2B | Services & Consulting, Revenue Share, Usage-Based SaaS | |
 Colossal | Healthcare & Life Sciences | Series C Extension | $10.32B | $120M (Sep 2025) | $545M | - | www.bizjournals.com/ | B2B | Services & Consulting, Government Contracts, Subscription SaaS | ||
 Colossal | Healthcare & Life Sciences | Series C Extension | $10.32B | $120M (Sep 2025) | $545M | 236 | Austin, Texas | www.colossal.com | B2B | Services & Consulting, Government Contracts, Data as a Service | |
 Whoop | Consumer & Commerce | Series G | $10.1B | $575M (Mar 2026) | $979.39M | 1,502 | Boston, Massachusetts | www.whoop.com | B2C | Hardware + Subscription, Subscription SaaS, Hardware Sales | |
 Neuralink | Healthcare & Life Sciences | Series E | $9.6B | $656.5M (May 2025) | $1.25B | 686 | Fremont, California | www.neuralink.com | B2B2C | Hardware Sales, Hardware + Subscription, Services & Consulting | |
 Intas Pharmaceuticals | Healthcare & Life Sciences | Secondary | $8.5B | $260M (Oct 2022) | $56.2M | 19,912 | Ahmedabad | www.intaspharma.com/ | B2B | Services & Consulting | |
 Commure | Healthcare & Life Sciences | Growth Equity | $7B | $70M (May 2026) | $877M | 1,577 | Mountain View, California | www.commure.com/ | B2B | Subscription SaaS, Usage-Based SaaS, Freemium | |
 Ro | Healthcare & Life Sciences | Series D Extension | $7B | $150M (Feb 2022) | $1.03B | 1,479 | New York City, New York | www.ro.co | B2C | Subscription SaaS, Services & Consulting | |
 Datavant | Healthcare & Life Sciences | M&A | $7B | (Jun 2021) | $80.5M | 7,157 | Phoenix, Arizona | www.datavant.com/ | B2B | Subscription SaaS, Usage-Based SaaS, Services & Consulting | |
 WeDoctor | Healthcare & Life Sciences | Series G | $6.7B | $66.88M (Dec 2022) | $1.64B | - | Hangzhou | www.guahao.com/ | B2B2C | Marketplace Commission, Subscription SaaS, Government Contracts, Services & Consulting, Hardware Sales | |
 Doctolib | Healthcare & Life Sciences | Growth Equity | $6.4B | $549M (Mar 2022) | $814.6M | 7 | Levallois-Perret | www.doctolib.fr/ | B2B | Subscription SaaS, Freemium, Hardware + Subscription, Payment Processing Fee | |
 Altos Labs | Healthcare & Life Sciences | VC Round | $6.33B | $3B (Jan 2022) | - | 562 | Redwood City, California | www.altoslabs.com/ | B2B | Services & Consulting | |
 Alan | FinTech | Series G | $6.3B | $550M (Jun 2026) | $1.4B | 1,487 | Paris | www.alan.com/ | B2B2C | Subscription SaaS, Usage-Based SaaS | |
 Benchling | Healthcare & Life Sciences | Series F | $6.1B | $100M (Nov 2021) | $405.05M | 810 | San Francisco, California | www.benchling.com | B2B | Subscription SaaS, Services & Consulting, Freemium | |
 NeuroVigil, Inc. | Healthcare & Life Sciences | Series B | $6B | $85M (Apr 2024) | $85.25M | 4 | Mountain View, California | www.neurovigil.com/ | B2B | Services & Consulting, Data as a Service | |
 Cityblock | Healthcare & Life Sciences | Series D | $5.7B | $374M (Sep 2021) | $867.7M | 787 | Brooklyn, New York | www.cityblock.com | B2B2C | Revenue Share, Government Contracts |
Companies are classified into this sector based on Caplight sector and vertical tagging, then ranked by most recent post-money valuation.
